Busulfan, Cyclophosphamide, Imatinib Mesylate and Autologous Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
Busulfan and cyclophosphamide are chemotherapy drugs which were designed to kill leukemia
cells. An autologous bone marrow transplant is given after treatment with busulfan and
cyclophosphamide to help in the recovery of blood and immune cells after this treatment.
Imatinib mesylate is a drug which helps to stop the growth of leukemia cells. It is given
after the transplant to help kill any remaining leukemia cells.
Before treatment, you will have a complete physical exam. You will have approximately 4
tablespoons of blood drawn for tests to check on the status of the disease, to check organ
functions, and to check for infectious diseases (hepatitis, HIV, etc.). You will have a
sample of bone marrow collected. To collect a bone marrow sample, an area of the hip or
chest bone is numbed with anaesthetic and a small amount of bone marrow is withdrawn through
a large needle. All of these tests are being done to make sure you are eligible for this
treatment. If you are found to have a "blast crisis," you will not be eligible to continue
on this study.
If you are eligible or if it has not already been done recently, you will be taken to the
operating room and have around 4-6 cups of bone marrow collected. The procedure will be
performed under general anesthesia. The procedure is similar to the bone marrow collection
at the start of the study, however, more bone marrow will be collected. The bone marrow
that is collected will be frozen and stored to be given back to you after high dose
chemotherapy. Before the procedure, you will be asked to donate blood (if possible). This
blood will be given back to you after the procedure to replace the bone marrow that was
collected. You may also need a blood transfusion from another donor.
For patients who cannot undergo the procedure of bone marrow harvesting or if not enough
bone marrow was collected during the bone marrow harvesting procedure, stem cells may be
collected from the blood. Normally, there are very few stem cells in the blood. Most of
them are in the bone marrow. To help move or "mobilize" the cells needed from your bone
marrow to your blood, you will be given injections under the skin once a day of a drug
called G-CSF. The injections may given by a nurse in the hospital, in the outpatient
setting, or you may learn how to give the injection yourself. Blood samples (1 tablespoon)
will be drawn every day to see if there are enough stem cells in your blood. After 4-6 days
of treatment with G-CSF, you will undergo a procedure called leukapheresis. This procedure
is similar to donating blood to a blood bank. Blood is collected and run through a machine
that processes the blood and separates the cells needed for transplantation, giving the rest
back to you. The separated cells are frozen and stored to give back you after high dose
chemotherapy. You may need up to 3 leukapheresis procedures to collect enough cells.
Patients who had adequate amounts of their bone marrow or blood stem cells harvested in the
past will not need additional harvesting of stem cells.
At a future time when the leukemia shows signs of growth, you will have a catheter (small,
flexible tube) inserted under the collar bone into a large vein in the chest. This catheter
will allow the chemotherapy drugs, fluids, and other medications to be given more easily.
You will have approximately 4 tablespoons of blood drawn for tests to check on the status of
the disease, to check organ functions, and to check for infectious diseases (hepatitis, HIV,
etc.). You will have a sample of bone marrow collected. You will also have heart (cardiac
ejection fraction) and lung function tests.
You will be admitted to the hospital to receive high dose chemotherapy. You will be given
busulfan by continuous injection (using the catheter) for 4 days, then you will be given
cyclophosphamide by a continuous injection (using the catheter) for 2 days. The amount of
busulfan you receive may be adjusted to help decrease the risk of developing side effects.
You may also receive antibiotics, fluids, and other medications if your doctor feels it is
necessary.
After high dose chemotherapy, you will be given your stored bone marrow or blood stem cells
back ("transplant"). They will be given back to you through the catheter to help restore
blood production and immunity after high dose chemotherapy. To help speed up the recovery
of white blood cells, you will also be given G-CSF by injection under the skin daily until
the white blood count has recovered (usually 2 to 3 weeks). You may also receive
antibiotics, fluids, and other medications if your doctor feels it is necessary. Blood
tests are repeated several times per week until blood counts are fully recovered and any
side effects of the high dose therapy have resolved.
After your blood counts have recovered, you will begin treatment with imatinib mesylate by
mouth for up to 1 year. You may also receive medications to help prevent infections for
around 6 months after the transplant. These medications are usually pills to help prevent
pneumonia and viral infections. While you are taking imatinib mesylate you will have blood
collected (1- 4 tablespoons) for routine tests . The frequency of these blood collections
will depend on your medical condition.
Around 1, 3, 6, 12, 18, and 24 months after transplant, you will have check-up visits. At
these visits, you will have blood collected (1- 4 tablespoons) for routine blood tests and
have a sample of bone marrow collected for tests. This bone marrow collection will be
repeated 3, 4, and 5 years after the transplant procedure.
This is an investigational study. All of the drugs used in this study are FDA approved and
are commercially available. Up to 50 participants will take part in this study. All will
be enrolled at M. D. Anderson.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of participants with CML alive in cytogenetic remission at one year following treatment
Cytogenetic complete remission confirmed via bone marrow examination for morphology, cytogenetics or Fluorescence in situ hybridization (FISH).
Baseline to 1 Year post treatment, up to 18 months
No
Marcos de Lima, MD
Study Chair
UT MD Anderson Cancer Center
United States: Institutional Review Board
ID02-672
NCT01003054
March 2005
October 2009
Name | Location |
---|---|
UT MD Anderson Cancer Center | Houston, Texas 77030 |